EUDAMED has moved from planning topic to operating requirement.
The European Commission has declared the first four EUDAMED modules functional: Actor Registration, UDI/Devices, Notified Bodies & Certificates, and Market Surveillance. The notice was published in the Official Journal of the European Union on November 27, 2025, triggering the six-month transition period for mandatory use.
For medical device and IVD manufacturers, this is no longer a future-state compliance conversation. It is a near-term operating requirement that touches regulatory strategy, UDI data, product records, quality processes, market access, and long-term data integrity and governance.
What you'll learn
- What the OJEU notice actually activates: which four EUDAMED modules move into the first mandatory-use wave, and what still sits outside it.
- Why May 28, 2026 changes your planning: how the six-month transition period shifts assumptions for medical device and IVD teams.
- Where manufacturers get stuck: common gaps in UDI data, device records, ownership, labeling logic, and submission readiness.
- How to build readiness: practical steps for governed data, cross-functional accountability, workflow testing, and ongoing maintenance.
- Why this isn't a one-time filing: what sustainable governance for updates, changes, and future module obligations looks like.
For medical device and IVD manufacturers, this is no longer a future-state compliance conversation. It is a near-term operating requirement that touches regulatory strategy, UDI data, product records, quality processes, market access, and long-term data governance.
What the webinar covers
Watch USDM Life Sciences' Jay Crowley for a focused, on-demand session on what this milestone activates, what still comes later, and how manufacturers should turn EUDAMED awareness into a practical readiness plan.
Session agenda
- What the OJEU notice activates: which EUDAMED modules are included in the first mandatory-use wave and what remains outside that wave.
- Why May 28, 2026 matters: how the transition period changes planning assumptions for medical device teams.
- Where manufacturers get stuck: common gaps in UDI data, device records, ownership, labeling logic, and submission readiness.
- How to build readiness: practical steps for governed data, cross-functional accountability, workflow testing, and ongoing maintenance.
Who should watch
- Regulatory Affairs leaders responsible for MDR, IVDR, UDI, and EUDAMED obligations
- Quality, labeling, data governance, and product master data teams supporting device registration
- IT and business system owners managing regulatory data sources, workflows, and integrations
- Medical device executives who need a defensible plan before deadlines drive the program for them
Why this matters now
EUDAMED readiness is not just a portal access issue. Manufacturers need governed device data, clear accountability, consistent interpretation of MDR/IVDR obligations, and processes that can support both initial registration and ongoing updates. Weak upstream data and unclear ownership can turn a regulatory milestone into delayed submissions, rework, and avoidable market-access risk.
The strongest readiness programs treat EUDAMED as part of a global UDI and regulatory data capability. That includes validating source data, aligning device and certificate records, testing submission workflows, and establishing governance for changes after the first registration wave. Because the Notified Bodies & Certificates module ties your registration to external parties, it also makes third-party risk management part of staying ready.
- Do you have a governed source of truth for UDI and device master data?
- Can your teams distinguish initial registration obligations from later update and maintenance work?
- Are labeling, regulatory, quality, and master data ownership decisions documented?
- Have submission workflows, integrations, and exception handling been tested before deadline pressure arrives?
EUDAMED readiness FAQ
Which EUDAMED modules become mandatory first?
The first mandatory-use wave covers the four modules the European Commission has declared functional: Actor Registration, UDI/Devices, Notified Bodies & Certificates, and Market Surveillance. The session walks through what each of these activates and what still sits outside the first wave.
What is the significance of May 28, 2026?
The notice published in the Official Journal of the European Union on November 27, 2025 triggered a six-month transition period, making the first four modules mandatory to use from May 28, 2026. That timeline is what turns EUDAMED from an optional, future-state topic into a near-term operating requirement.
Is EUDAMED readiness a portal access problem or a data problem?
Primarily a data and operating-model problem. The submission is the visible step, but the real work is governed UDI and device master data, clear ownership across regulatory, quality, labeling, and master data teams, and tested submission workflows. Weak upstream data and unclear ownership are where manufacturers get stuck.
Is EUDAMED a one-time registration?
No. Beyond the initial registration wave, manufacturers need governance for updates, changes, and future module obligations. The strongest programs treat EUDAMED as part of an ongoing, governed UDI and regulatory data capability rather than a single filing.
Who inside a manufacturer needs to be involved?
Readiness is cross-functional. Regulatory Affairs, Quality, labeling, product master data, and IT/business system owners all have work to do, and device executives need a defensible plan before deadlines drive the program for them.
Related USDM resources
- UDI, EU MDR, IVDR, and EUDAMED readiness
- EU MDR/IVDR EUDAMED Readiness: What Medical Device Manufacturers Need to Do Now
- EUDAMED Has Landed: The Two Big Deadlines, May 28 vs. Nov. 28
- EUDAMED Compliance: Your Most Pressing Questions Answered
For the official European Commission update, see EUDAMED: The four first modules will be mandatory to use as from 28 May 2026.